News|Articles|May 19, 2025
Investigational Imlifidase Shows Rapid and Sustained Improvement of Guillain-Barré Syndrome Symptoms
Author(s)Marco Meglio
Among patients with severe Guillain-Barré syndrome, imlifidase plus IVIg resulted in improved mobility, strength, and disability scores, with sustained benefit over a 6-month time period.
Advertisement
In an open-label, single-arm, phase 2 trial (NCT03943589), treatment with a single dose of Hansa Biopharma’s imlifidase, an IgG-cleaving antibody, followed by intravenous immunoglobulin (IVIg) led to swift and sustained enhancement of symptoms in patients with Guillain-Barré syndrome (GBS). Presented at the 2025 Peripheral Nerve Society (PNS) Annual Meeting , held May 17-20, in Edinburgh, Scotland, these data further reinforce the therapeutic potential of imlifidase in the treatment of GBS.1
After excluding patients re-diagnosed with other conditions, the study featured 27 individuals with confirmed severe GBS who received imlifidase 0.25 mg/kg intravenously within 12 days of symptom onset followed by IVIg (0.4 mg/kg/day for 5 days, 48 hours after imlifidase. The effects of imlifidase were observed quickly, as 37% of treated patients were able to walk independently within 1 week of treatment. In addition, participants demonstrated an improvement in muscle strength, reflected by mean of 10.7 points in Medical Research Council (MRC) sum score.
Led by Shahram Attarian, MD, PhD, head, Department of Neuromuscular Diseases and ALS, Hopitaux Universitaires de Marseille, treatment with imlifidase plus IVIg led to rapid functional improvement, with a median time of 6 days to achieve at least 1-grade gain on the GBS Disability Scale (GBS DS). In addition, the median time to independently walk for participants was 16 days on treatment.
After 8 weeks of treatment, 67% of patients were able to walk independently, 40.7% of patients had regained the ability to run, and 37% of the patients had improved by at least 3 points in the GBS DS. At the 6-month time point, 63% of treated participants were able to run or had no functional disability, considered GBS DS of 1 or less. Above all, the agent continued to show a safe and well tolerated profile, with no unexpected safety concerns.
READ MORE: Phase 2 ARDA Findings Support Development of Empasiprubart in Multifocal Motor Neuropathy
Imlifidase is an enzyme derived from Streptococcus pyogenes that cleaves all subclasses of human IgG antibodies. It acts rapidly, degrading circulating IgG within hours of administration, thereby preventing or interrupting IgG-mediated autoimmune attacks. To date, it is approved in the European Union for desensitizing kidney transplant patients and remains investigational for the treatment of GBS.
Within the GBS treatment landscape, imlifidase differs slightly from traditional plasma exchange and IVIg. IVIg, which neutralizes autoantibodies, has a slower onset, and may be suboptimal in severe cases. Plasma exchange, intended to physical remove autoantibodies, is resource-intensive and not always feasible. Imlifidase has the potential to act faster than existing therapies, although there is more data needed on its mechanism and therapeutic benefits.
Prior to the phase 2 study, imlifidase was assessed in several phase 1 trials, including a study of healthy male volunteers. Published in Clinical Kidney Journal in March 2024, the study demonstrated that the agent was well-tolerated and effectively cleaved IgG antibodies within hours of administration, confirming its rapid onset of action.2 Two other subsequent, independent phase 1-2 studies involving highly sensitized patients with kidney transplants also further supported imlifidase’s development. All told, data revealed that imlifidase effectively reduced or eliminated donor-specific antibodies, enabling successful transplantation in 24 of the 25 observed patients.3
REFERENCES
1. Attarian S, Magy L, Echaniz-Laguna A, et al. Outcomes in Patients with Severe Guillain-Barré Syndrome Treated with Imlifidase and Standardof-Care Immunoglobulin. Presented at: 2025 PNS Annual Meeting; May 17-20; Edinburgh, Scotland. Abstract O582.
2. Kanbay M, Copur S, Guldan M, et al. Imlifidase in kidney transplantation. Clinical Kidney Journ. 2024;17(3). doi:10.1093/ckj/sfae033
3. Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study. News release. Hansa Biopharma. October 17, 2023. Accessed May 19, 2025. https://www.hansabiopharma.com/media/press-releases/2023/imlifidase-demonstrated-90-patient-survival-and-82-graft-survival-at-five-years-in-extended-pooled-analysis-with-data-from-17-hmedides-14-study/
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
NeurologyLive® Brain Games: September 14, 2025September 14th 2025
NeurologyLive® Friday 5 — September 12, 2025September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
3
NeurologyLive® Brain Games: September 14, 2025
4
